Cat. No. Name Size Price Add Cart
KI0621XL6475 mg$488
XL64710 mg$768

Chemical Characteristic

Product NameXL647
SynonymsEXEL-7647
CAS No.651031-01-5
Molecular Weight 491.39
FormulaC24H25Cl2FN4O2
Chemical NameN-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-{[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy}-4-quinazolinamine
Smilesn1cnc(c2cc(c(cc12)OCC1C[C@H]2[C@H](CN(C2)C)C1)OC)Nc1c(c(c(cc1)Cl)Cl)F
Chemical Structure

Biological activities

XL647 is a novel spectrum-selective, reversible and ATP competitive kinase inhibitor. XL647 possesses potent inhibitory activity against the EGF and vascular endothelial growth factor receptor tyrosine kinase families, both wild-type (WT) and mutant vascular endothelial growth factor receptor tyrosine kinase families (EGFR).The IC50 of XL647 is 0.3, 16, and 1.5 nM against EGFR, ErbB2 and KDR, respectively. In contrast, XL647 inhibits Flt-4 and EphB4 with IC50 of 8.7 and 1.4 nM, respectively.[1] In vitro, XL647 inhibits wild type EGFR phosphorylation with an IC50 of 1 nM in squamous cell carcinoma cell line, Lx-1. XL647 inhibits the WT EGFR, with an IC50 value of 12 nM, in pCMV/Lx-1 cells. In A431 cells, XL647 reduces cell viability with an IC50 of 13 nM. Treatment with 10 µM XL647 results in an almost complete inhibition of EGFR, AKT, and ERK phosphorylation. In addition, XL647 inhibits cellular proliferation and EGFR pathway activation in the erlotinib-resistant H1975 cell line that harbors a double mutation (L858R and T790M) in the EGFR gene. [1] XL647 inhibits the EGFR T790M variant. XL647 also inhibits mutant forms of ErbB2 associated with lapatinib resistance. XL647 inhibits Ba/F3 cell viability with all 17 ErbB2 mutations including E812K and E719G.[2] XL647 shows potent and long-lived inhibition of the WT EGFR in vivo. XL647 substantially suppresses the growth of H1975 xenograft tumors. XL647 reduces both tumor EGFR signaling and tumor vessel density. Additionally, XL647, in contrast to erlotinib, substantially inhibits the growth and vascularization of MDA-MB-231 xenografts.[1]

Protocols

EXEL-7647 is formulated for oral administration by dissolution of the dry powder in sterile filtered ( 0.45 µm) saline ( 0.9%) or in sterile water for injection.[1]

References

[1] Gendreau SB, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res. 2007, 13(12): 3713-3723.
[2] Trowe T, et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res. 2008, 14(8): 2465-2475.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.